End-of-day quote
Shanghai S.E.
06:00:00 2024-04-24 pm EDT
|
5-day change
|
1st Jan Change
|
18.8
CNY
|
+3.01%
|
|
+6.33%
|
-3.59%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
7,959
|
6,339
|
6,268
|
4,845
|
4,671
|
-
|
Enterprise Value (EV)
1 |
7,959
|
6,339
|
6,268
|
4,845
|
4,671
|
4,671
|
P/E ratio
|
61.5
x
|
33.9
x
|
33
x
|
52.7
x
|
29.8
x
|
21.4
x
|
Yield
|
0.45%
|
0.59%
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
20.4
x
|
10.7
x
|
9.66
x
|
10.5
x
|
6.62
x
|
5.41
x
|
EV / Revenue
|
20.4
x
|
10.7
x
|
9.66
x
|
10.5
x
|
6.62
x
|
5.41
x
|
EV / EBITDA
|
53.1
x
|
27.6
x
|
24.1
x
|
28.4
x
|
23.1
x
|
17.1
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
5.19
x
|
3.76
x
|
3.41
x
|
2.54
x
|
2.27
x
|
2.11
x
|
Nbr of stocks (in thousands)
|
248,454
|
248,454
|
248,454
|
248,454
|
248,454
|
-
|
Reference price
2 |
32.03
|
25.51
|
25.23
|
19.50
|
18.80
|
18.80
|
Announcement Date
|
2/2/21
|
2/21/22
|
2/21/23
|
2/23/24
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
390.4
|
593.4
|
649.2
|
460.7
|
705.8
|
863.2
|
EBITDA
1 |
149.8
|
229.9
|
259.7
|
170.6
|
202
|
273.9
|
EBIT
1 |
130.4
|
204
|
229.1
|
117.3
|
180.1
|
253.1
|
Operating Margin
|
33.39%
|
34.38%
|
35.29%
|
25.47%
|
25.52%
|
29.32%
|
Earnings before Tax (EBT)
1 |
136.9
|
217.3
|
239.5
|
63.8
|
189
|
262
|
Net income
1 |
118.6
|
186.4
|
190.8
|
129.9
|
156.8
|
218.3
|
Net margin
|
30.37%
|
31.41%
|
29.39%
|
28.2%
|
22.22%
|
25.29%
|
EPS
2 |
0.5207
|
0.7521
|
0.7636
|
0.3700
|
0.6300
|
0.8800
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
0.1438
|
0.1504
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/2/21
|
2/21/22
|
2/21/23
|
2/23/24
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
10.3%
|
11.6%
|
10.8%
|
4.87%
|
7.56%
|
9.7%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
6.170
|
6.790
|
7.400
|
7.690
|
8.290
|
8.930
|
Cash Flow per Share
2 |
0.3100
|
0.5800
|
0.6300
|
1.080
|
0.1700
|
0.8000
|
Capex
1 |
30.5
|
91.3
|
138
|
25.8
|
-
|
-
|
Capex / Sales
|
7.8%
|
15.39%
|
21.29%
|
5.6%
|
-
|
-
|
Announcement Date
|
2/2/21
|
2/21/22
|
2/21/23
|
2/23/24
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -3.59% | 645M | | +73.17% | 12.38B | | -18.74% | 7.92B | | +16.15% | 7.2B | | +4.81% | 5.84B | | +5.99% | 5.01B | | +27.07% | 4.53B | | -21.67% | 3.88B | | -40.82% | 2.23B | | +1.49% | 2.02B |
Medical Equipment
|